Organised in partnership with:

Advanced Therapies – Opportunities and Challenges

14th November, London


Richard Barker

Founding Director,
Centre for the Advancement of Sustainable Medical Innovation (CASMI)

Steve Bates

Chief Executive Officer,
BioIndustry Association (BIA)

Eduardo Bravo

Chief Executive Officer,
& EBE President

Ian Campbell

Director for Health and Life Sciences,
Innovate UK

Barbara Freischem

Executive Director,
European Biopharmaceutical Enterprises (EBE)

Peter Goodfellow

Scientific Advisor,

Karen Hodgkin

Chief Operating Officer,
Cell Medica

Seigo Izumo

Senior Vice President for Regenerative Medicine,
Takeda Pharmaceuticals

Adrien Lemoine

VP Business Development & Operations,
Orchard Therapeutics

James McBlane

CAT Member,
Preclinical Assessor,
UK Medicines and Healthcare Products Regulatory Agency (MHRA)

Deborah Morrison

Senior Scientific Adviser,
National Institute for Health and Care Excellence (NICE)

Lord James O’Shaughnessy

Parliamentary Under Secretary of State for Health (Lords),
UK Government

Magda Papadaki

Head of Product and Process Innovation,
Association of the British Pharmaceutical Industry (ABPI)

Michaël Hocquemiller

Scientific Director,

Gabriele Proetzel,

Director, Regenerative Medicine,

Qasim Rafiq

Senior Lecturer,
Bioprocessing of Regenerative, Cellular and Gene Therapies,

Christian K Schneider

National Institute for Biological Standards and Control

Duane Schulthess

Managing Director,
Vital Transformation

Michael Stein

Chief Executive Officer and Chairman,

Keith Thompson

Chief Executive Officer,
Cell and Gene Therapy Catapult

Supported by: